Новости лечения вагинальной микробиоты в перименопаузальный период

Abstract

The aim of the research: to evaluate the clinical efficacy and prevention of relapses of inflammatory and degenerative processes of the vagina in patients in perimenopausal period with the drug Femheal. Materials and methods. The study included 40 women aged from 49 to 56 years in perimenopausal period with clinical and laboratory confirmation of nonspecific vulvovaginitis and degenerative processes of the vagina: held pH meter before the appointment of therapy Femheal, 7 days and 3 months after the application Femheal. According to the severity of menopausal disorders to treatment included menopausal hormonal therapy, lipid-lowering and antihypertensive drugs. Results. The use of complex therapy with the use Femheal helps to restore the vaginal microbiota, which is accompanied by disappearance of clinical manifestations nonspecific vulvovaginal (feeling pain in the abdomen, in the genitals, itching, burning, swelling, discomfort and disperion), by normalization of pH. This therapy was effective in the prevention of recurrence, and with an integrated approach to reproductive aging - improving the quality of life. Conclusion. Practicing obstetrician-gynecologists, introducing the pathogenesis of chronic nonspecific vulvovaginal and related violations, especially in a situation when the pathological condition has completely pathognomonic clinical and laboratory evidence, should exclude bacterial vaginosis, sexually transmitted infections, timely identification of changes in the vaginal environment through pH test. Given the high efficiency Femheal in our study and documented in international publications relative to the positive evaluation reattain of action of the drug in the complex treatment of nonspecific vulvovaginitis and prevention of their recurrence, recommended his application for restoration of the vaginal biotope. Key words: nonspecific vulvovaginitis, perimenopausal period, Femheal.